{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:41:34Z","timestamp":1782891694796,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ramb.2012.11.003","type":"journal-article","created":{"date-parts":[[2013,3,31]],"date-time":"2013-03-31T08:15:14Z","timestamp":1364717714000},"page":"186-198","source":"Crossref","is-referenced-by-count":70,"title":["Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review"],"prefix":"10.1016","volume":"59","author":[{"given":"Suelen Jorge","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liania Alves","family":"Luzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid Sousa","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Helen Carvalho","family":"Rond\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ramb.2012.11.003_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(89)90225-8","article-title":"Hypertriglyceridemia in the acquired immunodeficiency syndrome","volume":"86","author":"Grunfeld","year":"1989","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0010","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/01.aids.0000327512.76126.6e","article-title":"Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors","volume":"3","author":"Boccara","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1310\/HT0W-NX2N-U2BM-7LUU","article-title":"Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population","volume":"6","author":"Mehta","year":"2005","journal-title":"Clin Trials"},{"key":"10.1016\/j.ramb.2012.11.003_bib0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.2001.tb03908.x","article-title":"Cardiology and AIDS - HAART and the consequences","volume":"946","author":"Hoffmann","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.ramb.2012.11.003_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00006454-200301000-00018","article-title":"Metabolic complications of antiretroviral therapy in children","volume":"22","author":"Leonard","year":"2003","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.ramb.2012.11.003_bib0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1310\/hct0704-184","article-title":"Lipid profile during pregnancy in HIV-infected women","volume":"7","author":"Floridia","year":"2006","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.ramb.2012.11.003_bib0035","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1590\/S0066-782X2009001100019","article-title":"Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV","volume":"93","author":"Kramer","year":"2009","journal-title":"Arquivos Brasileiros de Cardiologia"},{"key":"10.1016\/j.ramb.2012.11.003_bib0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11883-010-0152-1","article-title":"Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection","volume":"13","author":"Troll","year":"2011","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1016\/j.ramb.2012.11.003_bib0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00041433-200402000-00011","article-title":"Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of \u2018systemic steatosis\u2019","volume":"15","author":"Balasubramanyam","year":"2004","journal-title":"Current Opinion in Lipidology"},{"key":"10.1016\/j.ramb.2012.11.003_bib0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00000441-200407000-00007","article-title":"Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults","volume":"328","author":"Monier","year":"2004","journal-title":"American Journal of the Medical Sciences"},{"issue":"Suppl 1","key":"10.1016\/j.ramb.2012.11.003_bib0055","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/00126334-200202011-00005","article-title":"Long-term exposure to lifelong therapies","volume":"29","author":"Powderly","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1258\/0956462011923714","article-title":"The metabolic toxicities of antiretroviral therapy","volume":"12","author":"Herman","year":"2001","journal-title":"International Journal of STD and AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1157\/13056691","article-title":"Cardiovascular risk in patients with chronic HIV-1 infection: a controversy with therapeutic, clinical and prognostic implications","volume":"22","author":"Dronda","year":"2004","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"issue":"1","key":"10.1016\/j.ramb.2012.11.003_bib0070","first-page":"11","article-title":"Lipids and AIDS","volume":"21","author":"Ducobu","year":"2000","journal-title":"Revue Medicale de Bruxelles"},{"issue":"Suppl 2","key":"10.1016\/j.ramb.2012.11.003_bib0075","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/00126334-200310012-00005","article-title":"HIV, HAART, and hyperlipidemia: balancing the effects","volume":"34","author":"Sherer","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0080","first-page":"202","article-title":"Dislipidemia y virus de inmunodeficiencia adquirida\/SIDA","volume":"21","author":"El\u00edas-Calles","year":"2010","journal-title":"Rev Cuba Endocrinol"},{"key":"10.1016\/j.ramb.2012.11.003_bib0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1749-6632.2001.tb03912.x","article-title":"Drugs and cardiotoxicity in HIV and AIDS","volume":"946","author":"Fantoni","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.ramb.2012.11.003_bib0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1468-1293.2009.00784.x","article-title":"Serum lipid profile in highly active antiretroviral therapy-na\u00efve HIV-infected patients in Cameroon: a case-control study","volume":"11","author":"Nguema\u00efm","year":"2010","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11745-009-3369-4","article-title":"Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population","volume":"45","author":"Fourie","year":"2010","journal-title":"Lipids"},{"key":"10.1016\/j.ramb.2012.11.003_bib0100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/apc.2007.0186","article-title":"High-density lipoprotein cholesterol in HIV-infected patients: evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition","volume":"22","author":"Bernal","year":"2008","journal-title":"Aids Patient Care and STDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9343(91)90536-7","article-title":"Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome","volume":"90","author":"Grunfeld","year":"1991","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body fat abnormalities in HIV infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3 Suppl","key":"10.1016\/j.ramb.2012.11.003_bib0120","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jn\/122.suppl_3.749","article-title":"The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS","volume":"122","author":"Grunfeld","year":"1992","journal-title":"Journal of Nutrition"},{"key":"10.1016\/j.ramb.2012.11.003_bib0125","first-page":"144","article-title":"Lipid profile in HIV\/AIDS patients in Nigeria","volume":"10","author":"Adewole","year":"2010","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.ramb.2012.11.003_bib0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2223\/JPED.1910","article-title":"Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed","volume":"85","author":"Sarni","year":"2009","journal-title":"Journal of Pediatrics"},{"key":"10.1016\/j.ramb.2012.11.003_bib0135","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.nut.2009.06.024","article-title":"Lipodystrophy, lipid profile changes, and low serum retinol and carotenoid levels in children and adolescents with acquired immunodeficiency syndrome","volume":"26","author":"Battistini","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.ramb.2012.11.003_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2223\/JPED.1961","article-title":"Lipodystrophy syndrome and cardiovascular risk factors in children and adolescents infected with HIV\/AIDS receiving highly active antiretroviral therapy","volume":"86","author":"Werner","year":"2010","journal-title":"Journal of Pediatrics"},{"key":"10.1016\/j.ramb.2012.11.003_bib0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1203\/01.pdr.0000228335.64894.26","article-title":"Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome","volume":"60","author":"Verkauskiene","year":"2006","journal-title":"Pediatric Research"},{"key":"10.1016\/j.ramb.2012.11.003_bib0150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/157016209789973691","article-title":"HIV-1 infection in subjects older than 70: a multicenter cross-sectional","volume":"7","author":"Mothe","year":"2009","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.ramb.2012.11.003_bib0155","unstructured":"US. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. In: Department of Health and Human Service. AIDSInfo 2011 [cited 2012 jan 21]. Available from: http:\/\/www.aidsinfo.nih.gov"},{"key":"10.1016\/j.ramb.2012.11.003_bib0160","first-page":"96","article-title":"HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk","volume":"10","author":"Zou","year":"2007","journal-title":"Cardiology"},{"key":"10.1016\/j.ramb.2012.11.003_bib0165","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1258\/ijsa.2008.008295","article-title":"Cardiovascular disease risk management in HIV patients, experiences from Greater Manchester","volume":"20","author":"Mallewa","year":"2009","journal-title":"International Journal of STD and AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1468-1293.2011.00917.x","article-title":"Lipid profiles for nevirapine vs. atazanavir\/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-na\u00efve HIV-1-infected patients (the ARTEN study)","volume":"12","author":"Podzamczer","year":"2011","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1310\/hct1201-24","article-title":"Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial","volume":"12","author":"MacInnes","year":"2011","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.ramb.2012.11.003_bib0180","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jmii.2010.08.003","article-title":"Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia","volume":"44","author":"Lu","year":"2011","journal-title":"Journal of Microbiology, Immunology, and Infection"},{"key":"10.1016\/j.ramb.2012.11.003_bib0185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","article-title":"Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care","volume":"25","author":"Crane","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0190","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3851\/IMP1675","article-title":"Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men","volume":"15","author":"Randell","year":"2010","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1549-8719.2010.00023.x","article-title":"Microcirculatory vascular dysfunction in HIV-1 infected patients receiving highly active antiretroviral therapy","volume":"17","author":"Palios","year":"2010","journal-title":"Microcirculation"},{"key":"10.1016\/j.ramb.2012.11.003_bib0200","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0205","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/135965350901400218","article-title":"Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir\/ritonavir, in pretreated children at 96 weeks","volume":"14","author":"Bunupuradah","year":"2009","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/apc.2009.0039","article-title":"Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue","volume":"23","author":"Calza","year":"2009","journal-title":"Aids Patient Care and STDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1310\/hct1006-356","article-title":"Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir\/lamivudine once daily in antiretroviral-na\u00efve HIV-1\u2013infected adult subjects","volume":"10","author":"Carosi","year":"2009","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.ramb.2012.11.003_bib0220","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/pds.1755","article-title":"Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1infected children: a retrospective cohort study","volume":"18","author":"Kim","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ramb.2012.11.003_bib0225","first-page":"867","article-title":"Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases","volume":"89","author":"Tao","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.ramb.2012.11.003_bib0230","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1293.2008.00685.x","article-title":"Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution","volume":"10","author":"Williams","year":"2009","journal-title":"HIV Medicine"},{"issue":"Suppl 10","key":"10.1016\/j.ramb.2012.11.003_bib0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0213-005X(08)76548-0","article-title":"Darunavir in treatment-na\u00efve patients. The ARTEMIS study","volume":"26","author":"Estrada","year":"2008","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"key":"10.1016\/j.ramb.2012.11.003_bib0240","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1258\/ijsa.2008.007322","article-title":"Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-na\u00efve patients with HIV-1 infection","volume":"19","author":"Calza","year":"2008","journal-title":"International Journal of STD and AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1590\/S1676-24442008000300004","article-title":"Dyslipidemia in HIV\/AIDS patients in antiretroviral therapy in a university hospital, Rio de Janeiro, Brazil","volume":"44","author":"Farhi","year":"2008","journal-title":"J Bras Patol Med Lab"},{"key":"10.1016\/j.ramb.2012.11.003_bib0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/135965350801300302","article-title":"Long-term efficacy and safety of first-line therapy with once-daily saquinavir\/ritonavir","volume":"13","author":"Ananworanich","year":"2008","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0255","first-page":"183","article-title":"Prevalence of cardiovascular risk in patients who make use of antiretroviral therapy","volume":"40","author":"Pupulin","year":"2008","journal-title":"Rev Bras Anal Clin"},{"key":"10.1016\/j.ramb.2012.11.003_bib0260","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jac\/dkn121","article-title":"First-line antiretroviral therapy with efavirenz or lopinavir\/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort","volume":"61","author":"Domingo","year":"2008","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0265","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1468-1293.2007.00541.x","article-title":"Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen","volume":"9","author":"Colafigli","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0270","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/INF.0b013e31816b4539","article-title":"Double boosted protease inhibitors, saquinavir, and lopinavir\/ritonavir, in nucleoside pretreated children at 48 weeks","volume":"27","author":"Kosalaraksa","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1016\/j.ramb.2012.11.003_bib0275","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/QAI.0b013e3181648e16","article-title":"Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children","volume":"47","author":"Tassiopoulos","year":"2008","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0280","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy","volume":"12","author":"Aurpibul","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0285","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1293.2006.00346.x","article-title":"A prospective, 96-week study of the impact of trizivir, combivir\/nelfinavir, and lamivudine\/stavudine\/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity","volume":"7","author":"Kumar","year":"2006","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0290","first-page":"193","article-title":"Hyperlipidemia and glucose intolerance in patients with HIV infection receiving antiretroviral therapy","volume":"48","author":"Castro-Sansores","year":"2006","journal-title":"Salud Publica de Mexico"},{"key":"10.1016\/j.ramb.2012.11.003_bib0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/135965350601100507","article-title":"Lopinavir\/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison","volume":"11","author":"De Luca","year":"2006","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0300","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1468-1293.2005.00325.x","article-title":"Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone","volume":"6","author":"Jones","year":"2005","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0305","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-5-2","article-title":"Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment","volume":"5","author":"Keiser","year":"2005","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.ramb.2012.11.003_bib0310","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/135965350501000807","article-title":"Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children","volume":"10","author":"Vigan\u00f2","year":"2005","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00126334-200307010-00005","article-title":"Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study","volume":"33","author":"Lucas","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.0014-2972.2001.00940.x","article-title":"Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome","volume":"32","author":"Christeff","year":"2002","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.ramb.2012.11.003_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00126334-200201010-00003","article-title":"Body habitus changes and metabolic alterations in protease inhibitor-na\u00efve HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli","year":"2002","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0330","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00002030-200112070-00007","article-title":"An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride\/low HDL levels in treated HIV patients","volume":"15","author":"Fauvel","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0335","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00126334-200108150-00004","article-title":"Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor","volume":"27","author":"Rakotoambinina","year":"2001","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0340","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1468-1293.2001.00057.x","article-title":"Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99","volume":"2","author":"Thi\u00e9baut","year":"2001","journal-title":"HIV Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0345","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1258\/0956462011923507","article-title":"Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy","volume":"12","author":"Vergis","year":"2001","journal-title":"International Journal of STD and AIDS"},{"issue":"9170","key":"10.1016\/j.ramb.2012.11.003_bib0350","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ramb.2012.11.003_bib0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/135965359900400305","article-title":"Lipid evaluation in HIV-1-positive patients treated with protease inhibitors","volume":"4","author":"Schmidt","year":"1999","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.ramb.2012.11.003_bib0360","doi-asserted-by":"crossref","first-page":"E549","DOI":"10.1152\/ajpendo.2001.280.4.E549","article-title":"Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism","volume":"280","author":"Hruz","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.ramb.2012.11.003_bib0365","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/00126334-200010001-00002","article-title":"Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review","volume":"25","author":"Graham","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.ramb.2012.11.003_bib0370","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2133.2000.03363.x","article-title":"Lipodystrophy associated with protease inhibitors","volume":"142","author":"Panse","year":"2000","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.ramb.2012.11.003_bib0375","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0753-3322(00)88101-9","article-title":"Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences","volume":"53","author":"Math\u00e9","year":"1999","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"9119","key":"10.1016\/j.ramb.2012.11.003_bib0380","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ramb.2012.11.003_bib0385","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0924-8579(03)00115-8","article-title":"Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management","volume":"22","author":"Calza","year":"2003","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"4 Suppl","key":"10.1016\/j.ramb.2012.11.003_bib0390","first-page":"III1","article-title":"Phenotyping. On reaching base camp (1950-1975)","volume":"87","author":"Fredrickson","year":"1993","journal-title":"Circulation"},{"issue":"Suppl 17","key":"10.1016\/j.ramb.2012.11.003_bib0395","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0213-005X(08)76615-1","article-title":"Efficacy of atazanavir in simplification regimens","volume":"26","author":"Zamora","year":"2008","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"issue":"Suppl 17","key":"10.1016\/j.ramb.2012.11.003_bib0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-005X(08)76616-3","article-title":"Efficacy of atazanavir in rescue therapy","volume":"26","author":"Portilla","year":"2008","journal-title":"Enfermedades Infecciosas y Microbiologia Clinica"},{"key":"10.1016\/j.ramb.2012.11.003_bib0405","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/108729102761882125","article-title":"Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens","volume":"16","author":"Moyle","year":"2002","journal-title":"Aids Patient Care and STDS"},{"key":"10.1016\/j.ramb.2012.11.003_bib0410","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"Friis-M\u00f8ller","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ramb.2012.11.003_bib0415","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/HJR.0b013e328336a150","article-title":"Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study","volume":"17","author":"Friis-M\u00f8ller","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"9622","key":"10.1016\/j.ramb.2012.11.003_bib0420","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ramb.2012.11.003_bib0425","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dub\u00e9","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ramb.2012.11.003_bib0430","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1086\/317491","volume":"31","author":"Dub\u00e9","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ramb.2012.11.003_bib0435","first-page":"911","article-title":"Blood lipid abnormalities during treatment with protease inhibitors","volume":"30","author":"Verg\u00e8s","year":"2001","journal-title":"Presse Medicale"},{"issue":"9311","key":"10.1016\/j.ramb.2012.11.003_bib0440","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0104423013000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0104423013000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:00:14Z","timestamp":1715144414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0104423013000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0104423013000110"],"URL":"https:\/\/doi.org\/10.1016\/j.ramb.2012.11.003","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}